EHD2 inhibits the invasive ability of lung adenocarcinoma and improves the prognosis of patients

Wei, Sheng; Shao, Jingjing; Wang, Jinming; Zhao, Tianye; Liu, Jia; Shen, Xiying; Wang, Yidan; Chen, Haizhen; Wang, Gaoren

doi:10.21037/jtd-22-842

Cited by 6 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, reducing the morbidity and mortality of LUAD has been a major global public health concern. Some biomarkers could predict the survival time of LUAD patients and inhibit or promote the progression of LUAD [ [19] , [20] , [21] , [22] ]. EHD2 protein expression is decreased in LUAD and is associated with lymph node metastasis, advanced tumor stage, and decreased survival, as well as being an independent prognostic factor in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

Wu,

Liu,

Luo

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Inhibition of EHD2 expression promoted the migration and invasion of A549 cells. Overexpression of EHD2 inhibited the migration and invasion of H1299 cells [ 19 ]. The expression of DDR1 in LUAD tissues is higher than that in normal tissues, and DDR1 overexpression is negatively correlated with poor prognosis in LUAD patients.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

Wu,

Liu,

Luo

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…With the rapid development of various omics technologies and bioinformatics, more and more genes have been identified as biomarkers for certain cancers for disease screening, diagnosis, prognosis, or further development as therapeutic targets corresponding biological reagents. Wei et al found that EHD2 can inhibit the invasive ability of LUAD, improve patient prognosis, and can be used as a prognostic biomarker for LUAD [ 30 ]. Huang et al showed through bioinformatics analysis and cellular experiments that high expression of GRSF1 promotes the occurrence and development of LUAD tumors and can be used as an effective prognostic biomarker for LUAD patients [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

CMaf-Inducing Protein Promotes LUAD Proliferation and Metastasis by Activating the MAPK/ERK Pathway

Wang²,

Qian

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Previous studies have shown that cMaf-inducing protein (CMIP) promotes tumorigenesis and progression, however, the role of CMIP in lung adenocarcinoma (LUAD) and its molecular mechanism remain unclear. Methods. In this study, the Human Protein Atlas and Kaplan–Meier Plotter database were used to analyze the expression and prognostic value of CMIP in LUAD. Then, the expression levels of CMIP in LUAD tissues and cells were detected by qRT-PCR and western blot. The lentiviral vector was used to establish a stable transfected cell line, and the transfection efficiency was detected by qRT-PCR. MTT assay, colony formation assay, transwell assay, and wound healing assay were used to evaluate the function of CMIP in LUAD. In addition, the effect of CMIP on the MAPK/ERK pathway in LUAD cells was analyzed by western blot. Results. The expression level of CMIP was significantly increased in LUAD cell and tissue samples, and the high expression of CMIP was associated with overall survival (OS) and progression-free survival (PFS) in LUAD patients. In vitro experiments showed that CMIP overexpression significantly promoted the proliferation, migration, and invasion of A549 cells. CMIP knockout significantly inhibited the proliferation, migration, and invasion of H1299 cells. In addition, it was observed that the expression levels of the MAPK/ERK pathway-related proteins were significantly increased in CMIP-overexpressed A549 cells, and promoted cell proliferation, migration, and invasion, while U0126 could significantly reverse the activation of the MAPK/ERK pathway by CMIP overexpression, and inhibit the proliferation, migration, and invasion of A549 cells. Conclusion. Our study shows that CMIP, as an oncogene, is associated with poor patient prognosis, and may promote the proliferation and metastasis of LUAD by activating the MAPK/ERK pathway. Therefore, CMIP may be a new potential therapeutic target for LUAD.

show abstract

“…The detailed IHC analysis was conducted according to a previous study ( 24 ). All early-stage LUAD tissues used in this study were placed in liquid nitrogen after surgery.…”

Section: Methodsmentioning

confidence: 99%

High-risk early-stage lung adenocarcinoma patients are identified by an immune-related circadian clock gene signature

Wang¹,

Zhang²,

Du³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background: Twenty-four-hour oscillations of circadian rhythms control comprehensive biological processes in the human body. In lung adenocarcinoma (LUAD), chronic circadian rhythm disruption is positively associated with tumorigenesis. However, few studies focus on circadian clock gene signatures (CGSs) for prognosis evaluation of patients with early-stage LUAD.Methods: In this study, we aimed to construct a robust prognostic circadian rhythm-related biomarker from multiple public databases, including the Gene Expression Omnibus database and The Cancer Genome Atlas database. The least absolute shrinkage and selection operator (LASSO)-penalized Cox regression model was performed to select optimal circadian clock gene pairs. Bioinformatic analyses were performed to estimate the abundance of different immune cells and immunohistochemical analyses were conducted to validate the differential proportion of tumor-infiltrating lymphocytes in different groups.Results: Results demonstrated that the CGS could accurately identify patients with early-stage LUAD at a high risk in the training dataset [hazard ratio (HR) =3.06; 95% confidence interval (CI): 2.47-3.78; P<0.001], testing dataset (HR =2.44; 95% CI: 1.74-3.43; P<0.001), and validation dataset (HR =2.09, 95% CI: 1.09-4.00; P=0.023). Bioinformatic and immunohistochemical analyses demonstrated that the abundance of tumor-infiltrating CD4 + T cells was higher in the low-CGS groups. Integration of the CGS and clinical characteristics improved the accuracy of the CGS in predicting overall survival (OS) of patients with earlystage LUAD. Conclusions:In conclusion, the CGS was an independent immune-related circadian biomarker that could identify early-stage LUAD patients with different OS.

show abstract

EHD2 inhibits the invasive ability of lung adenocarcinoma and improves the prognosis of patients

Cited by 6 publications

References 39 publications

Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

CMaf-Inducing Protein Promotes LUAD Proliferation and Metastasis by Activating the MAPK/ERK Pathway

High-risk early-stage lung adenocarcinoma patients are identified by an immune-related circadian clock gene signature

Contact Info

Product

Resources

About